Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose ...

A man who has suffered from hallucinations for nearly two decades said a new therapy being trialled in South Yorkshire had ...

An antibiotic commonly prescribed for acne management has been linked to a reduced chance of developing schizophrenia. In a ...

Panelists discuss how CT-155, a 16-week interactive digital application, met its primary end point in clinical trials by ...

Schizoaffective disorder and schizophrenia are separate mental disorders. Learn about both, including symptoms, risk factors, and treatment.

The funding will support the creation of personalized, AI-driven 'vital signs' from speech and language analysis to measure psychosis severity.

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

The phase 3 comeback story Bristol Myers Squibb investors were eagerly anticipating is not to be—at least not this year. | ...

Bristol Myers Squibb will enroll more patients in a key Phase 3 trial studying its drug Cobenfy in psychosis associated with ...